Panel endorses Merck's anti-clotting drug

Share this article:

Advising the FDA to “do its due diligence” about bleeding risk, an FDA panel voted 10-1 in favor of Merck's anti-clotting drug vorapaxar, which would have the brand name Zontivity, Reuters reports. The panel and Merck want to limit the drug's use to heart attack patients without a stroke history, because of an increased bleeding risk among stroke patients.

Aspirin, and Bristol-Myers Squibb's now off-patent Plavix (clopidogrel) seek the same goal—to prevent clots—but Reuters notes Merck's potential market peer works differently, by inhibiting a PAR-1 receptor.

The panel also says the drug should come with a weight minimum because lighter patients appear to be at a higher risk for bleeds.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.